Epigenetic targets are exciting new avenues for cancer drug discovery. Zhang and colleagues have designed the open-source EZH2 inhibitor JQEZ5 and shown antitumor efficacy in vitro and in vivo in preclinical studies in murine and human lung adenocarcinoma models expressing high levels of EZH2.

Original languageEnglish (US)
Pages (from-to)949-952
Number of pages4
JournalCancer discovery
Issue number9
StatePublished - Sep 2016

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Developing EZH2-targeted therapy for lung cancer'. Together they form a unique fingerprint.

Cite this